RxDoctor Payments DataLook up a doctor →

Sri Koneru, MD

Rheumatology · Mason, OHNPI 1811937071

Payments from drug & device makers

$16,089in general payments, 2019–2025

Across 1,159 payments — averaging $13.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$5K
  • UCB, Inc.$2K
  • Amgen$2K
  • Johnson & Johnson$2K
  • Lilly USA, LLC$1K
  • E.r. Squibb & Sons, L.L.C.$819
  • plus $3K from 24 others
$166in research payments, 2019–2025

Across 1 payment — averaging $165.96 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abiomed$166

What the payments were for

  • Food & beverage$15,59197%
  • Education$4983%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$16,089 in reported general payments places this provider in the 75th percentile of 255 rheumatology providers in Ohio.

See all rheumatology providers in Ohio

Medicare billing

Part B allowed, 2024
$954,407
Medicare patients
344
Services billed
73,372

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept43$309,178
Humira(Cf) PenAdalimumab38$254,300
Enbrel MiniEtanercept16$129,707
EnbrelEtanercept13$95,557
Xeljanz XrTofacitinib Citrate13$85,317
OrenciaAbatacept15$83,726
SimponiGolimumab12$68,962
MethotrexateMethotrexate Sodium572$11,302
Hydroxychloroquine Sulfate303$9,838
Mycophenolic AcidMycophenolate Sodium14$5,027
Leflunomide79$4,809
Mycophenolate Mofetil30$2,265
Prednisone317$2,068
Duloxetine Hcl28$1,609
Celecoxib33$1,333

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenEnbrel$2,303$95,55713 claims
E.r. Squibb & Sons, L.L.C.Orencia$819$83,72615 claims
Johnson & JohnsonSimponi$1,828$68,96212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 255 rheumatology providers in Ohio.

Other rheumatology in Mason

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →